X

Trial Profile

Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 61Cu-based NuriPro radiodiagnostic NUCLIDIUM (Primary) ; Piflufolastat F18
Indications Prostate cancer
Focus Adverse reactions

Most Recent Events

25 Oct 2024 New trial record
21 Oct 2024 According to a NUCLIDIUM media release, upon successful completion of the trial, NUCLIDIUM will advance the NuriProTM program into a Phase 1/2 theranostic clinical trial, evaluating both the 61Cu-based imaging agent alongside the 67Cu-based therapeutic candidate.
21 Oct 2024 According to a NUCLIDIUM media release, the first patient has been successfully imaged in a phase 1 clinical trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com